Circulation of polyclonal OXA-244-producing Escherichia coli lineages in Jerusalem, Israel
JAC-Antimicrobial Resistance · 30.10.2025 · 7 (6)
DOI: 10.1093/jacamr/dlaf210 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 13.11.2025. Verfasst von Janko Sattler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Machine Learning and Systems Biology, Max Planck Institute of Biochemistry, Martinsried, Germany. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and objectives OXA-244-producing Escherichia coli represents an emerging concern in Europe due to its rapid spread and difficult-to-detect phenotype. While other OXA-48-like carbapenemases emerged in Israel in 2007, the circulation of OXA-244-producing E. coli was only recently reported. We aimed to investigate the proportion of OXA-244 amongst OXA-48-like-producing E. coli in a tertiary care university hospital in Jerusalem, Israel, during 2024. We analysed their mode of acquisition, phylogeny, resistome, and the genetic context of blaOXA-244 in these isolates. Patients and methods In 2024, 171 patients were identified with OXA-48-like-producing E. coli from screening or clinical samples. Of these, 53 were selected using convenience sampling across the entire year for whole genome characterization using short-read sequencing and a subset also underwent long-read sequencing.
Results
Amongst the 53 sequenced OXA-48-like-producing E. coli, the majority harboured blaOXA-244 (n = 34), followed by blaOXA-48 (n = 11), and blaOXA-181 (n = 8). Of the 34 OXA-244-producing E. coli, transmission was classified as probably or possibly healthcare-associated for 88.2%, and community-acquired for 11.8%. The OXA-244-producing E. coli isolates belonged to 13 distinct STs that mainly matched internationally described clones. Core genome MLST demonstrated seven genomic clusters (≤10 allele differences), indicating close common ancestry. Long-read sequencing demonstrated that blaOXA-244 was chromosomally located within variants of the transposon Tn51098 across STs.
Conclusions
This study demonstrates the predominance of OXA-244-producing E. coli in a tertiary care hospital in Jerusalem, Israel among OXA-48-like-producing isolates. The clonal diversity points to ongoing unrecognized community transmission, necessitating targeted surveillance and control measures.
Autor:innen und Institutionen
- Department of Machine Learning and Systems Biology, Max Planck Institute of Biochemistry, Martinsried, Germany.
- Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
- Faculty of Medicine, Hebrew University, Jerusalem, Israel.
- Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
ORCID-Profile: Yonatan Oster, Karsten Borgwardt, Adrian Egli, Jacob Moran-Gilad
Zitieren
APA
Sattler, J., Oster, Y., Seth Smith, H. M. B., Gütlin, Y., Michael-Gayego, A., Reshef, D., Temper, V., Borgwardt, K., Egli, A., Strahilevitz, J., & Moran-Gilad, J. (2025). Circulation of polyclonal OXA-244-producing Escherichia coli lineages in Jerusalem, Israel. JAC-Antimicrobial Resistance, 7(6). https://doi.org/10.1093/jacamr/dlaf210
Vancouver
Sattler J, Oster Y, Seth Smith HMB, Gütlin Y, Michael-Gayego A, Reshef D, et al. Circulation of polyclonal OXA-244-producing Escherichia coli lineages in Jerusalem, Israel. JAC-Antimicrobial Resistance. 2025;7(6). doi:10.1093/jacamr/dlaf210
BibTeX
@article{Sattler2025,
author = {Sattler, Janko and Oster, Yonatan and Seth Smith, Helena M B and Gütlin, Yukino and Michael-Gayego, Ayelet and Reshef, Dan and Temper, Violeta and Borgwardt, Karsten and Egli, Adrian and Strahilevitz, Jacob and Moran-Gilad, Jacob},
title = {Circulation of polyclonal OXA-244-producing Escherichia coli lineages in Jerusalem, Israel},
journal = {JAC-Antimicrobial Resistance},
year = {2025},
volume = {7},
number = {6},
doi = {10.1093/jacamr/dlaf210}
}
EUVIMED